Stereospecific prevention by 17β‐estradiol of MPTP‐induced dopamine depletion in mice
Identifieur interne : 001224 ( Main/Corpus ); précédent : 001223; suivant : 001225Stereospecific prevention by 17β‐estradiol of MPTP‐induced dopamine depletion in mice
Auteurs : Sophie Callier ; Marc Morissette ; Michelle Grbois ; Thérèse Di PaoloSource :
- Synapse [ 0887-4476 ] ; 2000-09-15.
English descriptors
- KwdEn :
Abstract
Neuroprotective activity of estrogens is reported in Alzheimer disease and recently has also been suggested for Parkinson disease, a disease affecting more men than women. To characterize this estrogenic activity, we studied the effects of 17β‐ and 17α‐estradiol treatment (1 μg twice daily 5 days before, during the day of four MPTP (15 mg/kg) injections, and for the following 5 days) on dopamine striatal toxicity induced by the neurotoxin MPTP in retired breeder male C57BL/6 mice. Striatal dopamine concentrations and its metabolites dihydroxyphenylacetic acid and homovanillic acid measured by HPLC in MPTP mice that received 17β‐estradiol were comparable to control animals, whereas MPTP mice treated with saline or 17α‐estradiol showed important decreases of dopamine and its metabolites. Striatal serotonin and its metabolite 5‐hydroxyindoleacetic acid concentrations remained unchanged after MPTP and treatments with steroids. Striatal [3H]GBR 12935 binding autoradiography to the dopamine transporter was as extensively decreased and correlated with dopamine depletion in MPTP mice, whereas this transporter mRNA decrease in the substantia nigra pars compacta was less pronounced. Treatment with steroids did not significantly change [3H]GBR 12935 binding, whereas dopamine transporter mRNA levels were not significantly different from controls. Under the present paradigm in retired breeder male mice, our results show dopaminergic and stereospecificity of estradiol to augment dopamine levels in MPTP‐lesioned mice without protecting against the extensive loss of dopamine terminals and moderate cell body loss. Synapse 37:245–251, 2000. © 2000 Wiley‐Liss, Inc.
Url:
DOI: 10.1002/1098-2396(20000915)37:4<245::AID-SYN1>3.0.CO;2-5
Links to Exploration step
ISTEX:4D2CD72C7E2B927E2AF68157BB11DCFC5A9F3D2CLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Stereospecific prevention by 17β‐estradiol of MPTP‐induced dopamine depletion in mice</title>
<author><name sortKey="Callier, Sophie" sort="Callier, Sophie" uniqKey="Callier S" first="Sophie" last="Callier">Sophie Callier</name>
<affiliation><mods:affiliation>Centre de Recherches en Endocrinologie Moléculaire, Le Centre Hospitalier Universitaire de Québec, Pavillon CHUL, Québec, Qc, G1V 4G2, and Faculty of Pharmacy, Laval University, Québec, Qc, G1K 7P4, Canada</mods:affiliation>
</affiliation>
<affiliation><mods:affiliation>INSERM Unit 339, St.‐Antoine Hospital, 75012 Paris, France</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Morissette, Marc" sort="Morissette, Marc" uniqKey="Morissette M" first="Marc" last="Morissette">Marc Morissette</name>
<affiliation><mods:affiliation>Centre de Recherches en Endocrinologie Moléculaire, Le Centre Hospitalier Universitaire de Québec, Pavillon CHUL, Québec, Qc, G1V 4G2, and Faculty of Pharmacy, Laval University, Québec, Qc, G1K 7P4, Canada</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Grbois, Michelle" sort="Grbois, Michelle" uniqKey="Grbois M" first="Michelle" last="Grbois">Michelle Grbois</name>
<affiliation><mods:affiliation>Centre de Recherches en Endocrinologie Moléculaire, Le Centre Hospitalier Universitaire de Québec, Pavillon CHUL, Québec, Qc, G1V 4G2, and Faculty of Pharmacy, Laval University, Québec, Qc, G1K 7P4, Canada</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Di Paolo, Therese" sort="Di Paolo, Therese" uniqKey="Di Paolo T" first="Thérèse" last="Di Paolo">Thérèse Di Paolo</name>
<affiliation><mods:affiliation>Centre de Recherches en Endocrinologie Moléculaire, Le Centre Hospitalier Universitaire de Québec, Pavillon CHUL, Québec, Qc, G1V 4G2, and Faculty of Pharmacy, Laval University, Québec, Qc, G1K 7P4, Canada</mods:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:4D2CD72C7E2B927E2AF68157BB11DCFC5A9F3D2C</idno>
<date when="2000" year="2000">2000</date>
<idno type="doi">10.1002/1098-2396(20000915)37:4<245::AID-SYN1>3.0.CO;2-5</idno>
<idno type="url">https://api.istex.fr/document/4D2CD72C7E2B927E2AF68157BB11DCFC5A9F3D2C/fulltext/pdf</idno>
<idno type="wicri:Area/Main/Corpus">001224</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Stereospecific prevention by 17β‐estradiol of MPTP‐induced dopamine depletion in mice</title>
<author><name sortKey="Callier, Sophie" sort="Callier, Sophie" uniqKey="Callier S" first="Sophie" last="Callier">Sophie Callier</name>
<affiliation><mods:affiliation>Centre de Recherches en Endocrinologie Moléculaire, Le Centre Hospitalier Universitaire de Québec, Pavillon CHUL, Québec, Qc, G1V 4G2, and Faculty of Pharmacy, Laval University, Québec, Qc, G1K 7P4, Canada</mods:affiliation>
</affiliation>
<affiliation><mods:affiliation>INSERM Unit 339, St.‐Antoine Hospital, 75012 Paris, France</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Morissette, Marc" sort="Morissette, Marc" uniqKey="Morissette M" first="Marc" last="Morissette">Marc Morissette</name>
<affiliation><mods:affiliation>Centre de Recherches en Endocrinologie Moléculaire, Le Centre Hospitalier Universitaire de Québec, Pavillon CHUL, Québec, Qc, G1V 4G2, and Faculty of Pharmacy, Laval University, Québec, Qc, G1K 7P4, Canada</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Grbois, Michelle" sort="Grbois, Michelle" uniqKey="Grbois M" first="Michelle" last="Grbois">Michelle Grbois</name>
<affiliation><mods:affiliation>Centre de Recherches en Endocrinologie Moléculaire, Le Centre Hospitalier Universitaire de Québec, Pavillon CHUL, Québec, Qc, G1V 4G2, and Faculty of Pharmacy, Laval University, Québec, Qc, G1K 7P4, Canada</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Di Paolo, Therese" sort="Di Paolo, Therese" uniqKey="Di Paolo T" first="Thérèse" last="Di Paolo">Thérèse Di Paolo</name>
<affiliation><mods:affiliation>Centre de Recherches en Endocrinologie Moléculaire, Le Centre Hospitalier Universitaire de Québec, Pavillon CHUL, Québec, Qc, G1V 4G2, and Faculty of Pharmacy, Laval University, Québec, Qc, G1K 7P4, Canada</mods:affiliation>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Synapse</title>
<title level="j" type="abbrev">Synapse</title>
<idno type="ISSN">0887-4476</idno>
<idno type="eISSN">1098-2396</idno>
<imprint><publisher>John Wiley & Sons, Inc.</publisher>
<pubPlace>New York</pubPlace>
<date type="published" when="2000-09-15">2000-09-15</date>
<biblScope unit="volume">37</biblScope>
<biblScope unit="issue">4</biblScope>
<biblScope unit="page" from="245">245</biblScope>
<biblScope unit="page" to="251">251</biblScope>
</imprint>
<idno type="ISSN">0887-4476</idno>
</series>
<idno type="istex">4D2CD72C7E2B927E2AF68157BB11DCFC5A9F3D2C</idno>
<idno type="DOI">10.1002/1098-2396(20000915)37:4<245::AID-SYN1>3.0.CO;2-5</idno>
<idno type="ArticleID">SYN1</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0887-4476</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>17α‐estradiol</term>
<term>17β‐estradiol</term>
<term>MPTP</term>
<term>dopamine</term>
<term>dopamine transporter</term>
<term>striatum</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Neuroprotective activity of estrogens is reported in Alzheimer disease and recently has also been suggested for Parkinson disease, a disease affecting more men than women. To characterize this estrogenic activity, we studied the effects of 17β‐ and 17α‐estradiol treatment (1 μg twice daily 5 days before, during the day of four MPTP (15 mg/kg) injections, and for the following 5 days) on dopamine striatal toxicity induced by the neurotoxin MPTP in retired breeder male C57BL/6 mice. Striatal dopamine concentrations and its metabolites dihydroxyphenylacetic acid and homovanillic acid measured by HPLC in MPTP mice that received 17β‐estradiol were comparable to control animals, whereas MPTP mice treated with saline or 17α‐estradiol showed important decreases of dopamine and its metabolites. Striatal serotonin and its metabolite 5‐hydroxyindoleacetic acid concentrations remained unchanged after MPTP and treatments with steroids. Striatal [3H]GBR 12935 binding autoradiography to the dopamine transporter was as extensively decreased and correlated with dopamine depletion in MPTP mice, whereas this transporter mRNA decrease in the substantia nigra pars compacta was less pronounced. Treatment with steroids did not significantly change [3H]GBR 12935 binding, whereas dopamine transporter mRNA levels were not significantly different from controls. Under the present paradigm in retired breeder male mice, our results show dopaminergic and stereospecificity of estradiol to augment dopamine levels in MPTP‐lesioned mice without protecting against the extensive loss of dopamine terminals and moderate cell body loss. Synapse 37:245–251, 2000. © 2000 Wiley‐Liss, Inc.</div>
</front>
</TEI>
<istex><corpusName>wiley</corpusName>
<author><json:item><name>Sophie Callier</name>
<affiliations><json:string>Centre de Recherches en Endocrinologie Moléculaire, Le Centre Hospitalier Universitaire de Québec, Pavillon CHUL, Québec, Qc, G1V 4G2, and Faculty of Pharmacy, Laval University, Québec, Qc, G1K 7P4, Canada</json:string>
<json:string>INSERM Unit 339, St.‐Antoine Hospital, 75012 Paris, France</json:string>
</affiliations>
</json:item>
<json:item><name>Marc Morissette</name>
<affiliations><json:string>Centre de Recherches en Endocrinologie Moléculaire, Le Centre Hospitalier Universitaire de Québec, Pavillon CHUL, Québec, Qc, G1V 4G2, and Faculty of Pharmacy, Laval University, Québec, Qc, G1K 7P4, Canada</json:string>
</affiliations>
</json:item>
<json:item><name>Michelle Grbois</name>
<affiliations><json:string>Centre de Recherches en Endocrinologie Moléculaire, Le Centre Hospitalier Universitaire de Québec, Pavillon CHUL, Québec, Qc, G1V 4G2, and Faculty of Pharmacy, Laval University, Québec, Qc, G1K 7P4, Canada</json:string>
</affiliations>
</json:item>
<json:item><name>Thérèse Di Paolo</name>
<affiliations><json:string>Centre de Recherches en Endocrinologie Moléculaire, Le Centre Hospitalier Universitaire de Québec, Pavillon CHUL, Québec, Qc, G1V 4G2, and Faculty of Pharmacy, Laval University, Québec, Qc, G1K 7P4, Canada</json:string>
</affiliations>
</json:item>
</author>
<subject><json:item><lang><json:string>eng</json:string>
</lang>
<value>17β‐estradiol</value>
</json:item>
<json:item><lang><json:string>eng</json:string>
</lang>
<value>17α‐estradiol</value>
</json:item>
<json:item><lang><json:string>eng</json:string>
</lang>
<value>MPTP</value>
</json:item>
<json:item><lang><json:string>eng</json:string>
</lang>
<value>dopamine</value>
</json:item>
<json:item><lang><json:string>eng</json:string>
</lang>
<value>dopamine transporter</value>
</json:item>
<json:item><lang><json:string>eng</json:string>
</lang>
<value>striatum</value>
</json:item>
</subject>
<articleId><json:string>SYN1</json:string>
</articleId>
<language><json:string>eng</json:string>
</language>
<abstract>Neuroprotective activity of estrogens is reported in Alzheimer disease and recently has also been suggested for Parkinson disease, a disease affecting more men than women. To characterize this estrogenic activity, we studied the effects of 17β‐ and 17α‐estradiol treatment (1 μg twice daily 5 days before, during the day of four MPTP (15 mg/kg) injections, and for the following 5 days) on dopamine striatal toxicity induced by the neurotoxin MPTP in retired breeder male C57BL/6 mice. Striatal dopamine concentrations and its metabolites dihydroxyphenylacetic acid and homovanillic acid measured by HPLC in MPTP mice that received 17β‐estradiol were comparable to control animals, whereas MPTP mice treated with saline or 17α‐estradiol showed important decreases of dopamine and its metabolites. Striatal serotonin and its metabolite 5‐hydroxyindoleacetic acid concentrations remained unchanged after MPTP and treatments with steroids. Striatal [3H]GBR 12935 binding autoradiography to the dopamine transporter was as extensively decreased and correlated with dopamine depletion in MPTP mice, whereas this transporter mRNA decrease in the substantia nigra pars compacta was less pronounced. Treatment with steroids did not significantly change [3H]GBR 12935 binding, whereas dopamine transporter mRNA levels were not significantly different from controls. Under the present paradigm in retired breeder male mice, our results show dopaminergic and stereospecificity of estradiol to augment dopamine levels in MPTP‐lesioned mice without protecting against the extensive loss of dopamine terminals and moderate cell body loss. Synapse 37:245–251, 2000. © 2000 Wiley‐Liss, Inc.</abstract>
<qualityIndicators><score>7.144</score>
<pdfVersion>1.2</pdfVersion>
<pdfPageSize>594 x 792 pts</pdfPageSize>
<refBibsNative>true</refBibsNative>
<keywordCount>6</keywordCount>
<abstractCharCount>1674</abstractCharCount>
<pdfWordCount>4336</pdfWordCount>
<pdfCharCount>28259</pdfCharCount>
<pdfPageCount>7</pdfPageCount>
<abstractWordCount>234</abstractWordCount>
</qualityIndicators>
<title>Stereospecific prevention by 17β‐estradiol of MPTP‐induced dopamine depletion in mice</title>
<genre><json:string>article</json:string>
</genre>
<host><volume>37</volume>
<publisherId><json:string>SYN</json:string>
</publisherId>
<pages><total>7</total>
<last>251</last>
<first>245</first>
</pages>
<issn><json:string>0887-4476</json:string>
</issn>
<issue>4</issue>
<genre><json:string>Journal</json:string>
</genre>
<language><json:string>unknown</json:string>
</language>
<eissn><json:string>1098-2396</json:string>
</eissn>
<title>Synapse</title>
<doi><json:string>10.1002/(ISSN)1098-2396</json:string>
</doi>
</host>
<publicationDate>2000</publicationDate>
<copyrightDate>2000</copyrightDate>
<doi><json:string>10.1002/1098-2396(20000915)37:4>245::AID-SYN1>3.0.CO;2-5</json:string>
</doi>
<id>4D2CD72C7E2B927E2AF68157BB11DCFC5A9F3D2C</id>
<fulltext><json:item><original>true</original>
<mimetype>application/pdf</mimetype>
<extension>pdf</extension>
<uri>https://api.istex.fr/document/4D2CD72C7E2B927E2AF68157BB11DCFC5A9F3D2C/fulltext/pdf</uri>
</json:item>
<json:item><original>false</original>
<mimetype>application/zip</mimetype>
<extension>zip</extension>
<uri>https://api.istex.fr/document/4D2CD72C7E2B927E2AF68157BB11DCFC5A9F3D2C/fulltext/zip</uri>
</json:item>
<istex:fulltextTEI uri="https://api.istex.fr/document/4D2CD72C7E2B927E2AF68157BB11DCFC5A9F3D2C/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Stereospecific prevention by 17β‐estradiol of MPTP‐induced dopamine depletion in mice</title>
</titleStmt>
<publicationStmt><authority>ISTEX</authority>
<publisher>John Wiley & Sons, Inc.</publisher>
<pubPlace>New York</pubPlace>
<availability><p>WILEY</p>
</availability>
<date>2000</date>
</publicationStmt>
<notesStmt><note>MRC of Canada</note>
</notesStmt>
<sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Stereospecific prevention by 17β‐estradiol of MPTP‐induced dopamine depletion in mice</title>
<author><persName><forename type="first">Sophie</forename>
<surname>Callier</surname>
</persName>
<affiliation>Centre de Recherches en Endocrinologie Moléculaire, Le Centre Hospitalier Universitaire de Québec, Pavillon CHUL, Québec, Qc, G1V 4G2, and Faculty of Pharmacy, Laval University, Québec, Qc, G1K 7P4, Canada</affiliation>
<affiliation>INSERM Unit 339, St.‐Antoine Hospital, 75012 Paris, France</affiliation>
</author>
<author><persName><forename type="first">Marc</forename>
<surname>Morissette</surname>
</persName>
<affiliation>Centre de Recherches en Endocrinologie Moléculaire, Le Centre Hospitalier Universitaire de Québec, Pavillon CHUL, Québec, Qc, G1V 4G2, and Faculty of Pharmacy, Laval University, Québec, Qc, G1K 7P4, Canada</affiliation>
</author>
<author><persName><forename type="first">Michelle</forename>
<surname>Grbois</surname>
</persName>
<affiliation>Centre de Recherches en Endocrinologie Moléculaire, Le Centre Hospitalier Universitaire de Québec, Pavillon CHUL, Québec, Qc, G1V 4G2, and Faculty of Pharmacy, Laval University, Québec, Qc, G1K 7P4, Canada</affiliation>
</author>
<author><persName><forename type="first">Thérèse</forename>
<surname>Di Paolo</surname>
</persName>
<note type="correspondence"><p>Correspondence: Centre de Recherches en Endocrinologie Moléculaire, Le Centre Hospitalier Universitaire de Québec, Pavillon CHUL, 2705, Boulevard Laurier, Québec, Qc, Canada, G1V 4G2</p>
</note>
<affiliation>Centre de Recherches en Endocrinologie Moléculaire, Le Centre Hospitalier Universitaire de Québec, Pavillon CHUL, Québec, Qc, G1V 4G2, and Faculty of Pharmacy, Laval University, Québec, Qc, G1K 7P4, Canada</affiliation>
</author>
</analytic>
<monogr><title level="j">Synapse</title>
<title level="j" type="abbrev">Synapse</title>
<idno type="pISSN">0887-4476</idno>
<idno type="eISSN">1098-2396</idno>
<idno type="DOI">10.1002/(ISSN)1098-2396</idno>
<imprint><publisher>John Wiley & Sons, Inc.</publisher>
<pubPlace>New York</pubPlace>
<date type="published" when="2000-09-15"></date>
<biblScope unit="volume">37</biblScope>
<biblScope unit="issue">4</biblScope>
<biblScope unit="page" from="245">245</biblScope>
<biblScope unit="page" to="251">251</biblScope>
</imprint>
</monogr>
<idno type="istex">4D2CD72C7E2B927E2AF68157BB11DCFC5A9F3D2C</idno>
<idno type="DOI">10.1002/1098-2396(20000915)37:4<245::AID-SYN1>3.0.CO;2-5</idno>
<idno type="ArticleID">SYN1</idno>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><creation><date>2000</date>
</creation>
<langUsage><language ident="en">en</language>
</langUsage>
<abstract xml:lang="en"><p>Neuroprotective activity of estrogens is reported in Alzheimer disease and recently has also been suggested for Parkinson disease, a disease affecting more men than women. To characterize this estrogenic activity, we studied the effects of 17β‐ and 17α‐estradiol treatment (1 μg twice daily 5 days before, during the day of four MPTP (15 mg/kg) injections, and for the following 5 days) on dopamine striatal toxicity induced by the neurotoxin MPTP in retired breeder male C57BL/6 mice. Striatal dopamine concentrations and its metabolites dihydroxyphenylacetic acid and homovanillic acid measured by HPLC in MPTP mice that received 17β‐estradiol were comparable to control animals, whereas MPTP mice treated with saline or 17α‐estradiol showed important decreases of dopamine and its metabolites. Striatal serotonin and its metabolite 5‐hydroxyindoleacetic acid concentrations remained unchanged after MPTP and treatments with steroids. Striatal [3H]GBR 12935 binding autoradiography to the dopamine transporter was as extensively decreased and correlated with dopamine depletion in MPTP mice, whereas this transporter mRNA decrease in the substantia nigra pars compacta was less pronounced. Treatment with steroids did not significantly change [3H]GBR 12935 binding, whereas dopamine transporter mRNA levels were not significantly different from controls. Under the present paradigm in retired breeder male mice, our results show dopaminergic and stereospecificity of estradiol to augment dopamine levels in MPTP‐lesioned mice without protecting against the extensive loss of dopamine terminals and moderate cell body loss. Synapse 37:245–251, 2000. © 2000 Wiley‐Liss, Inc.</p>
</abstract>
<textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head>
<item><term>17β‐estradiol</term>
</item>
<item><term>17α‐estradiol</term>
</item>
<item><term>MPTP</term>
</item>
<item><term>dopamine</term>
</item>
<item><term>dopamine transporter</term>
</item>
<item><term>striatum</term>
</item>
</list>
</keywords>
</textClass>
</profileDesc>
<revisionDesc><change when="1999-08-17">Received</change>
<change when="1999-11-08">Registration</change>
<change when="2000-09-15">Published</change>
</revisionDesc>
</teiHeader>
</istex:fulltextTEI>
<json:item><original>false</original>
<mimetype>text/plain</mimetype>
<extension>txt</extension>
<uri>https://api.istex.fr/document/4D2CD72C7E2B927E2AF68157BB11DCFC5A9F3D2C/fulltext/txt</uri>
</json:item>
</fulltext>
<metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration>
<istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>John Wiley & Sons, Inc.</publisherName>
<publisherLoc>New York</publisherLoc>
</publisherInfo>
<doi registered="yes">10.1002/(ISSN)1098-2396</doi>
<issn type="print">0887-4476</issn>
<issn type="electronic">1098-2396</issn>
<idGroup><id type="product" value="SYN"></id>
</idGroup>
<titleGroup><title type="main" xml:lang="en" sort="SYNAPSE">Synapse</title>
<title type="short">Synapse</title>
</titleGroup>
</publicationMeta>
<publicationMeta level="part" position="40"><doi origin="wiley" registered="yes">10.1002/1098-2396(20000915)37:4<>1.0.CO;2-#</doi>
<numberingGroup><numbering type="journalVolume" number="37">37</numbering>
<numbering type="journalIssue">4</numbering>
</numberingGroup>
<coverDate startDate="2000-09-15">15 September 2000</coverDate>
</publicationMeta>
<publicationMeta level="unit" type="article" position="1" status="forIssue"><doi origin="wiley" registered="yes">10.1002/1098-2396(20000915)37:4<245::AID-SYN1>3.0.CO;2-5</doi>
<idGroup><id type="unit" value="SYN1"></id>
</idGroup>
<countGroup><count type="pageTotal" number="7"></count>
</countGroup>
<copyright ownership="publisher">Copyright © 2000 Wiley‐Liss, Inc.</copyright>
<eventGroup><event type="manuscriptReceived" date="1999-08-17"></event>
<event type="manuscriptAccepted" date="1999-11-08"></event>
<event type="firstOnline" date="2000-07-06"></event>
<event type="publishedOnlineFinalForm" date="2000-07-06"></event>
<event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.3.2 mode:FullText source:HeaderRef result:HeaderRef" date="2010-03-04"></event>
<event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-10"></event>
<event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-11-03"></event>
</eventGroup>
<numberingGroup><numbering type="pageFirst">245</numbering>
<numbering type="pageLast">251</numbering>
</numberingGroup>
<correspondenceTo>Centre de Recherches en Endocrinologie Moléculaire, Le Centre Hospitalier Universitaire de Québec, Pavillon CHUL, 2705, Boulevard Laurier, Québec, Qc, Canada, G1V 4G2</correspondenceTo>
<linkGroup><link type="toTypesetVersion" href="file:SYN.SYN1.pdf"></link>
</linkGroup>
</publicationMeta>
<contentMeta><countGroup><count type="figureTotal" number="2"></count>
<count type="tableTotal" number="0"></count>
<count type="referenceTotal" number="52"></count>
<count type="wordTotal" number="4945"></count>
</countGroup>
<titleGroup><title type="main" xml:lang="en">Stereospecific prevention by 17β‐estradiol of MPTP‐induced dopamine depletion in mice</title>
<title type="short" xml:lang="en">Stereospecific Estradiol Effect in MPTP‐Mice</title>
</titleGroup>
<creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1 #af2"><personName><givenNames>Sophie</givenNames>
<familyName>Callier</familyName>
</personName>
</creator>
<creator xml:id="au2" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Marc</givenNames>
<familyName>Morissette</familyName>
</personName>
</creator>
<creator xml:id="au3" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Michelle</givenNames>
<familyName>Grbois</familyName>
</personName>
</creator>
<creator xml:id="au4" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><givenNames>Thérèse</givenNames>
<familyName>Di Paolo</familyName>
</personName>
<contactDetails><email>therese.dipaolo@crchul.ulaval.ca</email>
</contactDetails>
</creator>
</creators>
<affiliationGroup><affiliation xml:id="af1" countryCode="CA" type="organization"><unparsedAffiliation>Centre de Recherches en Endocrinologie Moléculaire, Le Centre Hospitalier Universitaire de Québec, Pavillon CHUL, Québec, Qc, G1V 4G2, and Faculty of Pharmacy, Laval University, Québec, Qc, G1K 7P4, Canada</unparsedAffiliation>
</affiliation>
<affiliation xml:id="af2" countryCode="FR" type="organization"><unparsedAffiliation>INSERM Unit 339, St.‐Antoine Hospital, 75012 Paris, France</unparsedAffiliation>
</affiliation>
</affiliationGroup>
<keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">17β‐estradiol</keyword>
<keyword xml:id="kwd2">17α‐estradiol</keyword>
<keyword xml:id="kwd3">MPTP</keyword>
<keyword xml:id="kwd4">dopamine</keyword>
<keyword xml:id="kwd5">dopamine transporter</keyword>
<keyword xml:id="kwd6">striatum</keyword>
</keywordGroup>
<fundingInfo><fundingAgency>MRC of Canada</fundingAgency>
</fundingInfo>
<abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title>
<p>Neuroprotective activity of estrogens is reported in Alzheimer disease and recently has also been suggested for Parkinson disease, a disease affecting more men than women. To characterize this estrogenic activity, we studied the effects of 17β‐ and 17α‐estradiol treatment (1 μg twice daily 5 days before, during the day of four MPTP (15 mg/kg) injections, and for the following 5 days) on dopamine striatal toxicity induced by the neurotoxin MPTP in retired breeder male C57BL/6 mice. Striatal dopamine concentrations and its metabolites dihydroxyphenylacetic acid and homovanillic acid measured by HPLC in MPTP mice that received 17β‐estradiol were comparable to control animals, whereas MPTP mice treated with saline or 17α‐estradiol showed important decreases of dopamine and its metabolites. Striatal serotonin and its metabolite 5‐hydroxyindoleacetic acid concentrations remained unchanged after MPTP and treatments with steroids. Striatal [<sup>3</sup>
H]GBR 12935 binding autoradiography to the dopamine transporter was as extensively decreased and correlated with dopamine depletion in MPTP mice, whereas this transporter mRNA decrease in the substantia nigra pars compacta was less pronounced. Treatment with steroids did not significantly change [<sup>3</sup>
H]GBR 12935 binding, whereas dopamine transporter mRNA levels were not significantly different from controls. Under the present paradigm in retired breeder male mice, our results show dopaminergic and stereospecificity of estradiol to augment dopamine levels in MPTP‐lesioned mice without protecting against the extensive loss of dopamine terminals and moderate cell body loss. Synapse 37:245–251, 2000. © 2000 Wiley‐Liss, Inc.</p>
</abstract>
</abstractGroup>
</contentMeta>
</header>
</component>
</istex:document>
</istex:metadataXml>
<mods version="3.6"><titleInfo lang="en"><title>Stereospecific prevention by 17β‐estradiol of MPTP‐induced dopamine depletion in mice</title>
</titleInfo>
<titleInfo type="abbreviated" lang="en"><title>Stereospecific Estradiol Effect in MPTP‐Mice</title>
</titleInfo>
<titleInfo type="alternative" contentType="CDATA" lang="en"><title>Stereospecific prevention by 17β‐estradiol of MPTP‐induced dopamine depletion in mice</title>
</titleInfo>
<name type="personal"><namePart type="given">Sophie</namePart>
<namePart type="family">Callier</namePart>
<affiliation>Centre de Recherches en Endocrinologie Moléculaire, Le Centre Hospitalier Universitaire de Québec, Pavillon CHUL, Québec, Qc, G1V 4G2, and Faculty of Pharmacy, Laval University, Québec, Qc, G1K 7P4, Canada</affiliation>
<affiliation>INSERM Unit 339, St.‐Antoine Hospital, 75012 Paris, France</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">Marc</namePart>
<namePart type="family">Morissette</namePart>
<affiliation>Centre de Recherches en Endocrinologie Moléculaire, Le Centre Hospitalier Universitaire de Québec, Pavillon CHUL, Québec, Qc, G1V 4G2, and Faculty of Pharmacy, Laval University, Québec, Qc, G1K 7P4, Canada</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">Michelle</namePart>
<namePart type="family">Grbois</namePart>
<affiliation>Centre de Recherches en Endocrinologie Moléculaire, Le Centre Hospitalier Universitaire de Québec, Pavillon CHUL, Québec, Qc, G1V 4G2, and Faculty of Pharmacy, Laval University, Québec, Qc, G1K 7P4, Canada</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">Thérèse</namePart>
<namePart type="family">Di Paolo</namePart>
<affiliation>Centre de Recherches en Endocrinologie Moléculaire, Le Centre Hospitalier Universitaire de Québec, Pavillon CHUL, Québec, Qc, G1V 4G2, and Faculty of Pharmacy, Laval University, Québec, Qc, G1K 7P4, Canada</affiliation>
<description>Correspondence: Centre de Recherches en Endocrinologie Moléculaire, Le Centre Hospitalier Universitaire de Québec, Pavillon CHUL, 2705, Boulevard Laurier, Québec, Qc, Canada, G1V 4G2</description>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<typeOfResource>text</typeOfResource>
<genre type="article" displayLabel="article"></genre>
<originInfo><publisher>John Wiley & Sons, Inc.</publisher>
<place><placeTerm type="text">New York</placeTerm>
</place>
<dateIssued encoding="w3cdtf">2000-09-15</dateIssued>
<dateCaptured encoding="w3cdtf">1999-08-17</dateCaptured>
<dateValid encoding="w3cdtf">1999-11-08</dateValid>
<copyrightDate encoding="w3cdtf">2000</copyrightDate>
</originInfo>
<language><languageTerm type="code" authority="rfc3066">en</languageTerm>
<languageTerm type="code" authority="iso639-2b">eng</languageTerm>
</language>
<physicalDescription><internetMediaType>text/html</internetMediaType>
<extent unit="figures">2</extent>
<extent unit="references">52</extent>
<extent unit="words">4945</extent>
</physicalDescription>
<abstract lang="en">Neuroprotective activity of estrogens is reported in Alzheimer disease and recently has also been suggested for Parkinson disease, a disease affecting more men than women. To characterize this estrogenic activity, we studied the effects of 17β‐ and 17α‐estradiol treatment (1 μg twice daily 5 days before, during the day of four MPTP (15 mg/kg) injections, and for the following 5 days) on dopamine striatal toxicity induced by the neurotoxin MPTP in retired breeder male C57BL/6 mice. Striatal dopamine concentrations and its metabolites dihydroxyphenylacetic acid and homovanillic acid measured by HPLC in MPTP mice that received 17β‐estradiol were comparable to control animals, whereas MPTP mice treated with saline or 17α‐estradiol showed important decreases of dopamine and its metabolites. Striatal serotonin and its metabolite 5‐hydroxyindoleacetic acid concentrations remained unchanged after MPTP and treatments with steroids. Striatal [3H]GBR 12935 binding autoradiography to the dopamine transporter was as extensively decreased and correlated with dopamine depletion in MPTP mice, whereas this transporter mRNA decrease in the substantia nigra pars compacta was less pronounced. Treatment with steroids did not significantly change [3H]GBR 12935 binding, whereas dopamine transporter mRNA levels were not significantly different from controls. Under the present paradigm in retired breeder male mice, our results show dopaminergic and stereospecificity of estradiol to augment dopamine levels in MPTP‐lesioned mice without protecting against the extensive loss of dopamine terminals and moderate cell body loss. Synapse 37:245–251, 2000. © 2000 Wiley‐Liss, Inc.</abstract>
<note type="funding">MRC of Canada</note>
<subject lang="en"><genre>Keywords</genre>
<topic>17β‐estradiol</topic>
<topic>17α‐estradiol</topic>
<topic>MPTP</topic>
<topic>dopamine</topic>
<topic>dopamine transporter</topic>
<topic>striatum</topic>
</subject>
<relatedItem type="host"><titleInfo><title>Synapse</title>
</titleInfo>
<titleInfo type="abbreviated"><title>Synapse</title>
</titleInfo>
<genre type="Journal">journal</genre>
<identifier type="ISSN">0887-4476</identifier>
<identifier type="eISSN">1098-2396</identifier>
<identifier type="DOI">10.1002/(ISSN)1098-2396</identifier>
<identifier type="PublisherID">SYN</identifier>
<part><date>2000</date>
<detail type="volume"><caption>vol.</caption>
<number>37</number>
</detail>
<detail type="issue"><caption>no.</caption>
<number>4</number>
</detail>
<extent unit="pages"><start>245</start>
<end>251</end>
<total>7</total>
</extent>
</part>
</relatedItem>
<identifier type="istex">4D2CD72C7E2B927E2AF68157BB11DCFC5A9F3D2C</identifier>
<identifier type="DOI">10.1002/1098-2396(20000915)37:4<245::AID-SYN1>3.0.CO;2-5</identifier>
<identifier type="ArticleID">SYN1</identifier>
<accessCondition type="use and reproduction" contentType="copyright">Copyright © 2000 Wiley‐Liss, Inc.</accessCondition>
<recordInfo><recordContentSource>WILEY</recordContentSource>
<recordOrigin>John Wiley & Sons, Inc.</recordOrigin>
</recordInfo>
</mods>
</metadata>
<serie></serie>
</istex>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001224 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 001224 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= ParkinsonV1 |flux= Main |étape= Corpus |type= RBID |clé= ISTEX:4D2CD72C7E2B927E2AF68157BB11DCFC5A9F3D2C |texte= Stereospecific prevention by 17β‐estradiol of MPTP‐induced dopamine depletion in mice }}
![]() | This area was generated with Dilib version V0.6.23. | ![]() |